From the Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York; Horizon Pharma Inc., Lake Forest; College of Pharmacy, University of Illinois, Chicago, Illinois; Healthy Motivation, Bone and Joint Decade Global Alliance for Musculoskeletal Health, Santa Barbara, California; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; and Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds; University of Bristol; University of the West of England, Bristol, Bristol, UK; McGill University, Montreal, Quebec, Canada; Division of Medicine, The University of Adelaide, Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Singapore General Hospital, Duke-National University of Singapore (NUS) Medical School, Singapore.
E.T. Craig, MD, MHS, Johns Hopkins University School of Medicine; A.M. Orbai, MD, MHS, Johns Hopkins University School of Medicine; S. Mackie, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust; S.J. Bartlett, PhD, McGill University, and Johns Hopkins University School of Medicine; C.O. Bingham III, MD, Johns Hopkins University School of Medicine; S. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College; C. Hill, MBBS, MD, MSc, FRACP, Division of Medicine, The University of Adelaide, and Rheumatology Unit, The Queen Elizabeth Hospital; R. Holt, PharmD, MBA, Horizon Pharma Inc., and Adjunct Professor, College of Pharmacy, University of Illinois; A. Leong, MBA, Healthy Motivation, Bone and Joint Decade Global Alliance for Musculoskeletal Health; C. Karyekar, MD, PhD, Janssen Scientific Affairs LLC; Y.Y. Leung, MD, MB ChB, MRCP, FHKAM, FAMS, Singapore General Hospital, Duke-NUS Medical School; P. Richards, Patient Research Partner, University of Bristol; S. Halls, PhD, University of the West of England. Dr. Craig and Dr. Orbai are co-first authors.
J Rheumatol. 2019 Oct;46(10):1374-1378. doi: 10.3899/jrheum.181074. Epub 2019 Feb 15.
To improve measurement of stiffness in rheumatic disease.
Data presented included (1) 2 qualitative projects, (2) the rheumatoid arthritis (RA) stiffness patient-reported outcome measure (RAST), and (3) 3 items assessing stiffness severity, duration, and interference.
Stiffness is multidimensional and includes aspects of stiffness experience such as duration, severity, and effect. Stiffness items showed construct validity in RA. Further efforts are required to develop an instrument that will be taken through the Outcome Measures in Rheumatology (OMERACT) Filter 2.1 for instrument selection.
The research agenda for the group includes domain content voting for individual diseases, and development of stiffness item banks and disease-specific short forms.
提高风湿性疾病僵硬度的测量水平。
所呈现的数据包括：（1）2 个定性项目；（2）类风湿关节炎（RA）僵硬度患者报告结局测量（RAST）；（3）3 项评估僵硬严重程度、持续时间和干扰的项目。
僵硬是多维的，包括僵硬体验的各个方面，如持续时间、严重程度和影响。僵硬项目在 RA 中表现出结构有效性。需要进一步努力开发一种将通过风湿病终点测量（OMERACT）过滤器 2.1 进行仪器选择的仪器。
该小组的研究议程包括针对个别疾病的领域内容投票，以及僵硬项目库和疾病特异性简表的开发。
